
Instilling Hope for Life After Lymphoma
Dr. Manali Kamdar’s unique and empathetic approach to patient care and lymphoma research leaves a lasting impact on the lymphoma community.
On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…